Latest Breaking News On - Drug development discovery at usona institute - Page 1 : comparemela.com
Mind Medicine (MindMed) Inc (NASDAQ:MNMD): Making LSD Great Again
twst.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from twst.com Daily Mail and Mail on Sunday newspapers.
Interview with the CEO: Mind Medicine (MindMed) Inc (NASDAQ:MNMD)
twst.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from twst.com Daily Mail and Mail on Sunday newspapers.
MindMed Announces Chief Executive Officer Transition
News provided by
Share this article
Share this article
NEW YORK, June 9, 2021 /PRNewswire/ Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the Company ), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Company s co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief development officer, Robert Barrow, will assume the position of chief executive officer with immediate effect. The Company will also initiate a comprehensive search for a chief executive officer, in which Mr. Barrow will be a candidate, and Mr. Rahn will advise the Company during its leadership transition. The transition of the Company s leadership team will enable the Company to pursue aggressively its clinical development programs and development of its companion innovative digital techno
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
News provided by
Share this article
Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer
NEW YORK, Jan. 14, 2021 /PRNewswire/ MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer. Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA.
In his most recent position, Mr. Barrow served as Director of Drug Development & Discovery at the Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona s development programs in psychedelics. At Usona, Mr. Barrow was responsible for launching the Phase 2